By Colin Kellaher

 

Synlogic Inc. (SYBX) on Wednesday said it plans to study its SYNB1891 Synthetic Biotic medicine in combination with Roche Holding AG's (ROG.EB) cancer immunotherapy Tecentriq in patients with advanced solid tumors under a collaboration with the Swiss drugmaker.

Synlogic, a Cambridge, Mass., clinical-stage biopharmaceutical company, said it expects to file an investigational new drug application with the U.S. Federal Drug Administration to begin an open-label Phase 1 clinical trial evaluating SYNB1891 as a monotherapy and a combination treatment with Tecentriq.

Synlogic said it will sponsor the study, while Roche will provide the clinical supply of Tecentriq.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

May 22, 2019 08:04 ET (12:04 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Roche (QX) Charts.